Commercial

Pfizer deals extend patent life for a top-selling rare disease drug

BioPharma Dive

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Rare Disease

Read full story

pharminent April 28, 2026 (Last updated: April 29, 2026)

BioPharma Dive

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Rare Disease

Read full story

Related Stories

Lilly UK recruits ex-England cricketer as obesity champion

A year after Vertex’s big launch, pain drug research faces a pivotal moment

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

You May Have Missed

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Arthrosi drug trial in gout delivers for new owner Sobi

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC